"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 4 | 0 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 6 | 2 | 8 |
| 2007 | 2 | 1 | 3 |
| 2008 | 4 | 6 | 10 |
| 2009 | 7 | 3 | 10 |
| 2010 | 3 | 3 | 6 |
| 2011 | 3 | 5 | 8 |
| 2012 | 2 | 5 | 7 |
| 2013 | 1 | 1 | 2 |
| 2014 | 8 | 3 | 11 |
| 2015 | 3 | 0 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 7 | 2 | 9 |
| 2018 | 3 | 3 | 6 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.
-
Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke. Neurochem Int. 2022 09; 158:105375.
-
Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke. Vascul Pharmacol. 2021 12; 141:106904.
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
-
Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization. Transl Stroke Res. 2020 08; 11(4):762-775.
-
Results of the FUEL Trial. Circulation. 2020 02 25; 141(8):641-651.
-
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019 12; 157(6):1506-1517.e1.
-
Alveolar Macrophage Apoptosis-associated Bacterial Killing Helps Prevent Murine Pneumonia. Am J Respir Crit Care Med. 2019 07 01; 200(1):84-97.
-
Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study. Am J Physiol Heart Circ Physiol. 2019 05 01; 316(5):H1192-H1201.
-
NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. Pharmacol Res. 2019 04; 142:237-250.